QR код

Lysin (K)-specific demethylase 1 inhibition enhances proteasome inhibitor response and overcomes drug resistance in multiple myeloma

Abstract Background Multiple myeloma (MM) is an incurable plasma cell malignancy, accounting for approximately 1% of all cancers. Despite recent advances in the treatment of MM, due to the introduction of proteasome inhibitors (PIs) such as bortezomib (BTZ) and carfilzomib (CFZ), relapses and diseas...

Повний опис

Збережено в:
Автори: Cecilia Bandini, Elisabetta Mereu, Tina Paradzik, Maria Labrador, Monica Maccagno, Michela Cumerlato, Federico Oreglia, Lorenzo Prever, Veronica Manicardi, Elisa Taiana, Domenica Ronchetti, Mattia D’Agostino, Francesca Gay, Alessandra Larocca, Lenka Besse, Giorgio Roberto Merlo, Emilio Hirsch, Alessia Ciarrocchi, Giorgio Inghirami, Antonino Neri, Roberto Piva
Формат: Artigo
Мова:Inglês
Опубліковано: BMC 2023-08-01
Серія:Experimental Hematology & Oncology
Предмети:
Multiple myeloma
B-cell neoplasms
Proteasome inhibitors
Synthetic lethality
LSD1
Drug resistance
Онлайн доступ:https://doi.org/10.1186/s40164-023-00434-x
Теги: Додати тег
Немає тегів, Будьте першим, хто поставить тег для цього запису!

Схожі ресурси